Open Access<p>Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study</p>
Author(s) -
Enrico Torre,
Giacomo Matteo Bruno,
S. Di Matteo,
Chiara Martinotti,
Maria Chiara Valentino,
Luigi Carlo Bottaro,
Giorgio Lorenzo Colombo
Publication year - 2020
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s240183
Subject(s) - medicine , dulaglutide , gliclazide , sulfonylurea , metformin , insulin glargine , basal insulin , basal (medicine) , diabetes mellitus , type 2 diabetes , insulin , medical prescription , endocrinology , pharmacology , exenatide
Diabetes represents a relevant public health problem worldwide due to its growing prevalence and socioeconomic burden, principally due to the development of macrovascular and microvascular complications as well as to the continuous launch of new and even more expensive drugs. The aim of our study is to evaluate the economic impact of dulaglutide, a weekly GLP-1 receptor agonist, on the treatment of diabetic patients as an alternative to both high dose sulphonylureas and insulin basalization at the failure of oral therapies alone. We carried out a cost-effectiveness analysis developed considering the economic implications of recent clinical studies regarding cardiovascular risk drug effects and especially of REWIND studies outcomes, focusing on the impact of weight changes on HRQoL.